This stealth company is building a reprogrammable ADAR sensor platform to detect disease-associated RNAs and produce engineered proteins to manipulate cell states without permanent genome editing.

Triveni Bio uses state of the art antibody discovery and optimization strategies, to selectively inhibit extracellular enzymes that, when overactive, can cause broad inflammatory response.